Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.48 |
| ▸ | GGT1 | P19440 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544041 | 0.87 | ACHE (0.69) | ACHETSHRCYP3A4MAPK1KDM4E | |
| SCHEMBL3188087 | 0.86 | KDM4E (0.50) | ACHETSHRCYP3A4PIK3CAMAPK1 | |
| SCHEMBL362353 | 0.83 | PTGS2 (0.57) | ACHETSHRMAPK1KDM4EHSD17B10 | |
| SCHEMBL9297160 | 0.82 | MAPK1 (0.61) | ACHETSHRMAPK1KDM4EHSD17B10 | |
| SCHEMBL27833214 | 0.82 | ESR1 (0.44) | ACHETSHRCYP3A4PIK3CAMAPK1 | |
| SCHEMBL742810 | 0.82 | ACHE (0.62) | ACHETSHRCYP3A4MAPK1KDM4E | |
| SCHEMBL31229899 | 0.82 | ACHE (0.62) | ACHETSHRCYP3A4MAPK1KDM4E | |
| SCHEMBL1231281 | 0.82 | PTGS2 (0.55) | ACHETSHRMAPK1KDM4EHSD17B10 | |
| SCHEMBL5328398 | 0.81 | MAPK1 (0.46) | ACHETSHRCYP3A4MAPK1KDM4E | |
| SCHEMBL10607470 | 0.80 | PTPN1 (0.54) | ACHETSHRCYP3A4MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0550866-B1 | Process for the preparation of vinyl-substituted aromatics from arylamines | HOECHST AG (DE) | 1996-10-09 | — | — | EP | claimed |
| US-5475176-A | Process for preparing vinyl-substituted aromatic compounds from arylamines | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | claimed |
| EP-0550866-A2 | Process for the preparation of vinyl-substituted aromatics from arylamines | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-14 | — | — | EP | claimed |
| US-20230150936-A1 | ANALOGS OF N,N,N-TRIMETHYL-4-PHOSPHORYLOXYTRYPTAMINE | TERRAN BIOSCIENCES INC. | 2023-05-18 | — | — | US | disclosed |
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| EP-2573069-A2 | Inhibitors of histone deacetylase and prodrugs thereof | MethylGene Inc. (CA) | 2013-03-27 | — | — | EP | disclosed |
| CN-101094827-B | Benzene compound having two or more substituents | DAIICHI SANKYO CO LTD | 2012-06-13 | — | — | CN | disclosed |
| US-RE43343-E1 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| EP-2276756-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2011-11-30 | — | — | EP | disclosed |
| WO-2011137054-A1 | NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-03 | — | — | WO | disclosed |
| CN-101094827-A | Benzene compound having two or more substituents | SANKYO CO (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-RE39850-E1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2007-09-18 | — | — | US | disclosed |
| EP-1748046-A2 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2007-01-31 | — | — | EP | disclosed |
| US-6541661-B1 | For treating cell proliferative diseases and conditions | METHYLGENE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| EP-1233958-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001038322-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-05-31 | — | — | WO | disclosed |
| EP-0550866-B1 | Process for the preparation of vinyl-substituted aromatics from arylamines | HOECHST AG (DE) | 1996-10-09 | — | — | EP | disclosed |
| US-5475176-A | Process for preparing vinyl-substituted aromatic compounds from arylamines | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| EP-0550866-A2 | Process for the preparation of vinyl-substituted aromatics from arylamines | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150936-A1 | ANALOGS OF N,N,N-TRIMETHYL-4-PHOSPHORYLOXYTRYPTAMINE | PNMT, HTR4, HTR5A | ACHE 780/4885TSHR 1767/4885CYP3A4 2156/4885 |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | ACHE 2341/4885TSHR 4034/4885CYP3A4 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.